Get the Stockscreener App
19.17
0.21%
-0.04
After Hours:
19.16
-0.01
-0.05%
Dbv Technologies Adr stock is traded at $19.17, with a volume of 387.06K.
It is down -0.21% in the last 24 hours and up +46.45% over the past month.
DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Its main product candidate under development is Viaskin Peanut for the treatment of peanut-allergic patients. In addition, the company also has earlier-stage food allergy programs, including Viaskin Milk and Eosinophilic Esophagitis, or EoE.
See More
Previous Close:
$19.21
Open:
$19.31
24h Volume:
387.06K
Relative Volume:
1.10
Market Cap:
$769.36M
Revenue:
-
Net Income/Loss:
$-102.09M
P/E Ratio:
-18.26
EPS:
-1.05
Net Cash Flow:
$-108.72M
1W Performance:
+0.74%
1M Performance:
+46.45%
6M Performance:
+109.28%
1Y Performance:
+520.39%
1-Day Range:
$18.78
$19.45
1-Week Range:
$18.69
$19.90
52-Week Range:
$3.15
$26.18
Dbv Technologies Adr Stock (DBVT) Company Profile
Name
Dbv Technologies Adr
Sector
Industry
Phone
33(0)155427878
Address
107 AVENUE DE LA REPUBLIQUE, CHATILLON
Compare DBVT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DBVT
Dbv Technologies Adr
|
19.17 | 770.97M | 0 | -102.09M | -108.72M | -1.05 |
|
VRTX
Vertex Pharmaceuticals Inc
|
453.36 | 115.12B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
771.87 | 81.34B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.65 | 52.48B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
840.95 | 51.59B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
174.04 | 37.13B | 447.02M | -1.18B | -906.14M | -6.1812 |
Dbv Technologies Adr Stock (DBVT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-15-25 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-03-25 | Initiated | Guggenheim | Buy |
| May-29-25 | Resumed | Goldman | Sell |
| Jan-04-23 | Upgrade | Societe Generale | Hold → Buy |
| Dec-16-22 | Downgrade | Goldman | Neutral → Sell |
| May-10-22 | Downgrade | Goldman | Buy → Neutral |
| Sep-14-21 | Upgrade | Societe Generale | Hold → Buy |
| Jan-22-21 | Downgrade | Societe Generale | Hold → Sell |
| Nov-02-20 | Upgrade | Societe Generale | Sell → Hold |
| Aug-06-20 | Downgrade | Societe Generale | Buy → Sell |
| Aug-05-20 | Reiterated | H.C. Wainwright | Buy |
| Mar-17-20 | Downgrade | Stifel | Buy → Hold |
| Jan-09-20 | Upgrade | Stifel | Hold → Buy |
| Dec-16-19 | Initiated | Citigroup | Buy |
| Sep-05-19 | Resumed | Morgan Stanley | Equal-Weight |
| Jun-17-19 | Initiated | Goldman | Buy |
| Dec-20-18 | Downgrade | Barclays | Overweight → Equal Weight |
| Dec-20-18 | Downgrade | BofA/Merrill | Buy → Underperform |
| Dec-20-18 | Downgrade | Jefferies | Buy → Hold |
| Dec-20-18 | Downgrade | Stifel | Buy → Hold |
| Oct-31-17 | Upgrade | Societe Generale | Sell → Hold |
| Oct-24-17 | Downgrade | Societe Generale | Buy → Sell |
| Oct-23-17 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jun-23-17 | Initiated | Deutsche Bank | Buy |
| Mar-16-17 | Upgrade | Societe Generale | Hold → Buy |
| Sep-26-16 | Initiated | JMP Securities | Mkt Outperform |
| Dec-03-15 | Initiated | Barclays | Overweight |
| Oct-23-15 | Initiated | BofA/Merrill | Buy |
View All
Dbv Technologies Adr Stock (DBVT) Latest News
How M&A Unlocked A Biotech Rebound In 2025— And What Comes Next? - Benzinga
Sidus Space, Starfighters Space And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session - Benzinga
Honeywell, Intuitive Machines And Other Big Stocks Moving Lower In Monday's Pre-Market Session - Sahm
DBV Technologies (NASDAQ:DBVT) Shares Gap Down on Insider Selling - Defense World
European ADRs Started The Week Higher, Led By Biotech - Finimize
H.C Wainwright and Citizens Raise PT on DBV Technologies (DBVT) Following Phase 3 VITESSE Trial Result - Finviz
Stock Market Today 21.12.2025 - ts2.tech
HC Wainwright Boosts Earnings Estimates for DBV Technologies - Defense World
DBV Technologies (NASDAQ:DBVT) Given New $45.00 Price Target at Citizens Jmp - Defense World
DBV Technologies S.A. (NASDAQ:DBVT) Receives Average Rating of “Moderate Buy” from Analysts - Defense World
HC Wainwright Has Positive Outlook for DBVT FY2026 Earnings - Defense World
Birkenstock, Insmed And Other Big Stocks Moving Lower In Thursday's Pre-Market Session - Benzinga
DBV Technologies (NASDAQ:DBVT) Sets New 12-Month High on Analyst Upgrade - Defense World
European Stocks On Wall Street Delivered Modest Moves For Investors - Finimize
Crude Oil Rises Over 1%; General Mills Earnings Top Views - Benzinga
Toro, DBV Technologies, Udemy, ABM Industries And Other Big Stocks Moving Higher On Wednesday - Benzinga
Citizens raises DBV Technologies stock price target to $45 on Viaskin Peanut success By Investing.com - ca.investing.com
Pre Market Movers: DBVT, YCBD, KYTX Set The Pace - RTTNews
Citizens raises DBV Technologies stock price target to $45 on Viaskin Peanut success - Investing.com UK
DBV Technologies receive positive results in key study with peanut patch - medwatch.com
Why Aditxt Shares Are Trading Higher By Around 63%; Here Are 20 Stocks Moving Premarket - Benzinga
Cantor Fitzgerald Upgrades DBV Technologies (NASDAQ:DBVT) to “Strong-Buy” - Defense World
DBV Technologies stock soars after positive Phase 3 trial results - Investing.com
DBV Technologies Reports Positive Phase 3 Trial Results - TipRanks
DBV Technologies Announces Positive Topline Results from Phase 3 VITESSE Trial of VIASKIN® Peanut Patch in Peanut Allergic Children Aged 4-7 Years - The Manila Times
DBV Technologies Announces Positive Topline Results from - GlobeNewswire
Peanut Allergy Patch For Kids? DBV Technologies Advances Toward FDA Filing - Sahm
DBV Technologies (NASDAQ:DBVT) Shares Gap DownTime to Sell? - MarketBeat
Micron Technology To Rally More Than 24%? Here Are 10 Top Analyst Forecasts For Monday - Benzinga
This SiTime Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday - Benzinga
DBV Technologies stock price target raised to $35 from $20 at H.C. Wainwright - Investing.com
DBV Technologies stock initiated with Overweight rating at Cantor Fitzgerald By Investing.com - Investing.com Nigeria
DBV Technologies stock initiated with Overweight rating at Cantor Fitzgerald - Investing.com
European Companies Trading In The US Notched Gains This Week - Finimize
What is DBV Technologies ADR (DBVT) Stock Return on Shareholders’ Capital? - setenews.com
Are Smart Investors Making the Right Decision? Snow Lake Resources Ltd (LITM) - setenews.com
Vivo Capital LLC Takes Position in DBV Technologies S.A. $DBVT - MarketBeat
Total assets of DBV Technologies SA Sponsored ADR – LSX:A40WEX - TradingView
DBV Technologies (NASDAQ:DBVT) Coverage Initiated at Guggenheim - Defense World
Check Out Netskope Inc (NTSK)’s Trade Data Rather Than the Analysts’ Views - Setenews
Taking on analysts’ expectations and winning: DBV Technologies ADR (DBVT) - setenews.com
DBV Technologies stock initiated with Buy rating at Guggenheim - Investing.com
12 Health Care Stocks Moving In Friday's Pre-Market Session - Sahm
Healthy Upside Potential: Safe Pro Group Inc (SPAI) - Setenews
European Drugmakers And Banks Put ADRs In The Green - Finimize
DBV Technologies S.A. (NASDAQ:DBVT) Given Consensus Recommendation of “Hold” by Brokerages - Defense World
RFK Jr Rejects Early Exposure Theory On Rising Peanut Allergies, Says Aluminum-Based Vaccines Are The Reason - Sahm
European ADRs Slip As Gains And Losses Balance Out - Finimize
Dbv Technologies Adr Stock (DBVT) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.90%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):